TMPRSS2:ETS Fusions and Clinicopathologic Characteristics of Prostate Cancer Patients from Eastern China |
Dong, Jun
(Department of Urology, Huadong Hospital, Fudan University)
Xiao, Li (Department of Pathology, Huadong Hospital, Fudan University) Sheng, Lu (Department of Urology, Huadong Hospital, Fudan University) Xu, Jun (Department of Urology, Huadong Hospital, Fudan University) Sun, Zhong-Quan (Department of Urology, Huadong Hospital, Fudan University) |
1 | Wang J, Cai Y, Ren C, Ittmann M (2006). Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res, 66, 8347-51. DOI ScienceOn |
2 | Sun QP, Li LY, Chen Z, et al (2010). Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J Mol Diagn, 12, 718-24. DOI ScienceOn |
3 | Tomlins SA, Bjartell A, Chinnaiyan AM, et al (2009). ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol, 56, 275-86. DOI ScienceOn |
4 | Tomlins SA, Rhodes DR, Perner S, et al (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644-8. DOI ScienceOn |
5 | Wang JJ, Liu YX, Wang W et al (2012). Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China. Asian Pac J Cancer Prev, 13, 4935-8. 과학기술학회마을 DOI ScienceOn |
6 | Xiang H, Ling ZX, Sun K, et al (2011). Detection and significance of fusion gene between TMPRSS2 and ETS transcription factor genes in fresh prostatic cancer tissues in Chinese patients. Zhonghua Bing Li Xue Za Zhi, 40, 187-8. |
7 | Meiers I, Waters DJ, Bostwick DG (2007). Preoperative prediction of multifocal prostate cancer and application of focal therapy: Review 2007. Urology, 70, 3-8. DOI ScienceOn |
8 | Magi-Galluzzi C, Tsusuki T, Elson P, et al (2011). TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate, 71, 489-97. DOI ScienceOn |
9 | Mao X, Yu Y, Boyd LK, et al (2010). Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res, 70, 5207-12. DOI |
10 | Mehra R, Han B, Tomlins SA, et al (2007). Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res, 67, 7991-5. DOI ScienceOn |
11 | Miyagi Y, Sasaki T, Fujinami K, et al (2010). ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol, 23, 1492-8. DOI ScienceOn |
12 | Mosquera JM, Mehra R, Regan MM, et al (2009). Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res, 15, 4706-11. DOI ScienceOn |
13 | Rawal S, Young D, Williams M, et al (2013). Low frequency of the ERG oncogene alterations in prostate cancer patients from India. J Cancer, 4, 468-72. DOI ScienceOn |
14 | Ren S, Peng Z, Mao JH, et al (2012). RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicing. Cell Res, 22, 806-21. DOI |
15 | Rubin MA, Maher CA, Chinnaiyan AM (2011). Common gene rearrangements in prostate cancer. J Clin Oncol, 29, 3659-68. DOI ScienceOn |
16 | Clark J, Attard G, Jhavar S, et al (2008). Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene, 27, 1993-2003. DOI ScienceOn |
17 | Sim HG, Cheng CW (2005). Changing demography of prostate cancer in Asia. Eur J Cancer, 41, 834-45. DOI ScienceOn |
18 | Dai MJ, Chen LL, Zheng YB, et al (2008). Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer. Zhonghua yi xue za zhi, 88, 669-73. |
19 | Barry M, Perner S, Demichelis F, Rubin MA (2007). TMPRSS2-ERG fusion heterogeneity in Multifocal prostate cancer: Clinical and biologic implications. Urology, 70, 630-3. DOI ScienceOn |
20 | Furusato B, Gao CL, Ravindranath L, et al (2008). Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Modern Pathol, 21, 67-75. DOI |
21 | Furusato B, van Leenders GJ, Trapman J, et al (2011). Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int, 61, 409-14. DOI ScienceOn |
22 | Gronberg H (2003). Prostate cancer epidemiology. Lancet, 361, 859-64. DOI ScienceOn |
23 | Hessels D, Smit FP, Verhaegh GW, et al (2007). Detection of TMPRSS2: ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res, 13, 5103-8. DOI ScienceOn |
24 | Lee K, Chae JY, Kwak C, Ku JH, Moon KC (2010). TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology, 76, 7-13. |
25 | Cerveira N, Ribeiro FR, Peixoto A, et al (2006). TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia, 8, 826-32. DOI |
26 | Attard G, Reid AH, Yap TA, et al (2008). PhaseⅠclinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol, 26, 4563-71. DOI ScienceOn |
27 | Soller MJ, Isaksson M, Elfving P, et al (2006). Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer, 45, 717-9. DOI ScienceOn |